Steun en bronnen
We verwijzen naar organisaties en gepubliceerde bronnen die we vertrouwen. igg4.org is onafhankelijk, zonder industriefinanciering of sponsor. Een vermelding hier is een credit, geen poortwachter.
Belangrijkste medische literatuur
De gepubliceerde bronnen achter deze site. Waar mogelijk linken we naar een versie die je volledig kunt lezen, anders naar het publicatierecord. Dit is informatie en vervangt je specialist niet.
1.Della-Torre E, Talarico R, Ballarin J, et al. Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework. Lancet Rheumatol 2025;7(1):e64-e71
Bron lezen2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72(1):7-19
Bron lezen3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract 2024;8(2):rkae020
Bron lezen4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open 2019;4(Suppl 1):e000787
Bron lezen5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics 2025;15(18):2299
Bron lezen6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology 2020;59(Suppl 3):iii123-iii131
Bron lezen7.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67(7):1688-1699
Bron lezen8.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.
Bron lezen9.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database Syst Rev 2025;(8):CD016094
Bron lezen10.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.
Bron lezen11.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.
Bron lezen12.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.
Bron lezen13.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.
Bron lezen14.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Semin Diagn Pathol 2024;41(2):45-53
Bron lezen15.Reisch M, Spindelböck WJ, Hodl I, Pietsch D, Rainer F, Kickinger D, Sutic A, Thiel J, Stradner M. Azathioprine as maintenance therapy for IgG4-related diseases. Rheumatology International 2026;46(3):47.
Bron lezen16.Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease: a retrospective single-center cohort study focusing on rituximab. Rheumatology International 2026;46:33.
Bron lezen17.Taranto S, Bernardo L, Mauro A, Perrone A, Tamborino A, Giani T. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges. Children (Basel) 2025;12(7):888.
Bron lezen18.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).
Bron lezen19.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.
Bron lezen20.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.
Bron lezen21.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.
Bron lezen22.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.
Bron lezen23.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther 2026;28(1):96
Bron lezen24.Della-Torre E, Baker MC, Zhang W, et al; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med, published online 2 June 2026.
Bron lezen25.Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Annals of the Rheumatic Diseases, 2026.
Bron lezen26.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.
Bron lezen27.Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab 2024;109(7):1657-1683
Bron lezen28.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013;99(3):277-280
Bron lezen29.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.
Bron lezen30.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(1):236-245
Bron lezen31.Mahajan A, Tinianow A, Katz G. IgG4-Related disease: From diagnosis to remission. Best Practice & Research Clinical Rheumatology 2025;39:102108.
Bron lezen32.Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis 2024;83(5):651-660
Bron lezen33.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, European Alliance of Associations for Rheumatology
Bron lezen34.Choosing Wisely Canada, Allergy and Clinical Immunology recommendations, Canadian Society of Allergy and Clinical Immunology, updated May 2025
Bron lezen35.Yang F, Wang T, Liu Y. Risk factors for relapse of IgG4-related disease: a systematic review and meta-analysis. Clin Rheumatol 2025;44:4137-4147
Bron lezen36.Angarola E, Pasqua A, Castro HM, Cáceres A, Spina JC, Casciato P. Clinical characteristics, disease course, and chronic organ damage in a real-world cohort of IgG4-related disease: insights from an Interdisciplinary Unit. Medicina Clínica 2026;166:107317
Bron lezen37.Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 2025;157:103487
Bron lezen38.Koster MJ, Ghaffar U, Duong SQ, et al. Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clin Exp Rheumatol 2022;40:751-757
Bron lezen39.Dattani R, Barwick TD, El Wardany G, et al; RaDaR Rare Disease Group. An international patient-centred study of retroperitoneal fibrosis. QJM 2022;115(3):148-154
Bron lezen40.Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910
Bron lezen41.So H, Choi SJ, Park S, et al. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021. Sci Rep 2025;15:37273
Bron lezen42.American College of Rheumatology. IgG4-Related Disease (IgG4-RD). Patient information page, updated February 2025.
Bron lezen43.Gwozdz-Broczkowska A. Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework. Rheumatol Int 2026;46(8):232.
Bron lezen44.US Food and Drug Administration. RAYOS (prednisone) delayed-release tablets, prescribing information, revision 12/2019.
Bron lezen45.Liu Q, Zheng Y, Sturmlechner I, et al. IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease. J Clin Invest 2024;134(16):e178692.
Bron lezen46.FAI2R. Maladie associee aux IgG4: les reponses a vos questions.
Bron lezen47.Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62(4):e48-e88.
Bron lezen48.European Medicines Agency. MabThera (rituximab), Summary of Product Characteristics.
Bron lezen49.European Medicines Agency. Nordimet (methotrexate), Summary of Product Characteristics.
Bron lezen50.US Food and Drug Administration. IMURAN (azathioprine) 50-mg scored tablets, product information, revision 12/2018.
Bron lezen51.Yu K, Gao H, Liu S, et al. Perception of recurrence risk in patients with IgG4-related disease: a descriptive phenomenological study. Rheumatol Adv Pract 2025;9(1):rkae148.
Bron lezen52.Newman JH, Shaver A, Sheehan JH, et al; Undiagnosed Disease Network. IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med 2019;7(6):e686.
Bron lezen53.Karamya ZA, Kovacs A, Illes D, Czako B, Fazekas A, Farkas N, Hegyi P, Czako L. Prevalence of autoimmune pancreatitis in pancreatic resection for suspected malignancy: a systematic review and meta-analysis. BMC Gastroenterol 2024;24:278.
Bron lezen54.Dures E, Farisogullari B, Santos EJF, et al. 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2024;83(10):1260-1267.
Bron lezen55.Motor J, Gajewska A, Cienkowski K, et al. IgG4-related disease: focus on digestive system involvement. Front Immunol 2025;16:1584107.
Bron lezen56.Orphanet. Enfermedad sistemica relacionada con IgG4 (ORPHA:596448), Spanish version.
Bron lezen57.Orphanet. IgG4-gerelateerde systemische ziekte (ORPHA:596448), Dutch version.
Bron lezen58.Orphanet. Maladie systemique liee a la presence d'anticorps IgG4 (ORPHA:596448), French version.
Bron lezen59.Orphanet. IgG4-related systemic disease (ORPHA:596448), German version.
Bron lezen60.European Medicines Agency. Uplizna (inebilizumab), European public assessment report.
Bron lezen61.Erasmus MC. IgG4-gerelateerde ziekte, patient information.
Bron lezen62.Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74(6):1171-1177.
Bron lezen63.Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 2017;12(9):e0183844.
Bron lezen64.ClinicalTrials.gov registry record NCT04520451. An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Participants With IgG4-Related Disease. Phase 2, completed. Sponsor: Principia Biopharma, a Sanofi Company.
Bron lezen65.ClinicalTrials.gov registry record NCT07190196. A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease (RILIEF). Recruiting. Sponsor: Sanofi.
Bron lezen66.Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, Kleine-Tebbe J; EAACI Task Force. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008;63(7):793-796.
Bron lezen67.Orphanet. IgG4-related systemic disease (ORPHA:596448).
Bron lezen68.Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS). Ficha tecnica prednisona, CIMA.
Bron lezen69.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4. Haute Autorite de Sante, with FAI2R and CERAINOM-IgG4, November 2025.
Bron lezen70.Het Oogziekenhuis Rotterdam. IgG4-gerelateerde orbitale ziekte, patient information.
Bron lezen71.Imperial College Healthcare NHS Trust. RPF and IgG4-RD (retroperitoneal fibrosis and immunoglobulin-4 related disease), specialist nephrology service.
Bron lezen
National clinical guidance
De links hieronder leiden buiten deze site, om je te helpen zelf verder te zoeken. We controleren ze niet en bevelen ze niet aan, en we verdienen niets aan het vermelden ervan. Anders dan onze eigen bronnen hierboven, zijn ze door ons niet gecontroleerd op oorsprong of juistheid. Bevestig belangrijke zaken altijd bij je specialist.
1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.
Bron lezen
Product information (regulatory)
De links hieronder leiden buiten deze site, om je te helpen zelf verder te zoeken. We controleren ze niet en bevelen ze niet aan, en we verdienen niets aan het vermelden ervan. Anders dan onze eigen bronnen hierboven, zijn ze door ons niet gecontroleerd op oorsprong of juistheid. Bevestig belangrijke zaken altijd bij je specialist.
1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA
Bron lezen
Patient information from specialist centres
De links hieronder leiden buiten deze site, om je te helpen zelf verder te zoeken. We controleren ze niet en bevelen ze niet aan, en we verdienen niets aan het vermelden ervan. Anders dan onze eigen bronnen hierboven, zijn ze door ons niet gecontroleerd op oorsprong of juistheid. Bevestig belangrijke zaken altijd bij je specialist.
1.Het Oogziekenhuis Rotterdam, IgG4-Gerelateerde Orbitale Ziekte (IgG4-related orbital disease), patient information. Recognised Dutch expertise centre for rare orbital conditions.
Bron lezen2.Imperial College Healthcare NHS Trust, RPF and IgG4-RD service: specialist multidisciplinary service for retroperitoneal fibrosis and IgG4-related disease.
Bron lezen
Nuttige websites
De links hieronder leiden buiten deze site, om je te helpen zelf verder te zoeken. We controleren ze niet en bevelen ze niet aan, en we verdienen niets aan het vermelden ervan. Anders dan onze eigen bronnen hierboven, zijn ze door ons niet gecontroleerd op oorsprong of juistheid. Bevestig belangrijke zaken altijd bij je specialist.
- European Federation for IgG4-related disease
- IgG4ward! Foundation
- IgG4ward! Academy (online learning course)
- Asociación Española de Pacientes con Enfermedad Relacionada con IgG4 (AE-IgG4)
- Association Française du Syndrome et de la maladie associée aux IgG4 (AFRIGG4)
- Cleveland Clinic — IgG4-related disease
- MedLink Neurology — IgG4-related disease: neurological manifestations
- Orphanet, the portal for rare diseases: IgG4-related systemic disease (ORPHA:596448)
- ERN ReCONNET — IgG4-related disease (European Reference Network)
- Massachusetts General Hospital — IgG4-Related Systemic Disease Program
- FAI2R — Maladie associée aux IgG4 (réseau français des maladies rares, espace patients)
- IgG4-Syndrom — Uniklinikum Erlangen (Patienteninformation)
- ZIPSE — Zentrales Informationsportal über seltene Erkrankungen: IgG4-assoziierte Erkrankung
- FEDER — Enfermedad asociada a IgG4 (Federación Española de Enfermedades Raras)
Deze assistent deelt informatie met bronnen en kan je niet diagnosticeren of je arts vervangen. Zoek bij een noodgeval eerst dringende hulp.
